Torrey Pines Investment

What Torrey Pines Investment does

Torrey Pines Investment LLC is a privately held specialty life-science venture capital firm founded in 2012 and headquartered at 12730 High Bluff Drive, Suite 100, San Diego, California. The firm invests in early-stage biotech and pharmaceutical assets targeting clinical proof-of-concept within a three-year horizon, with a therapeutic focus on central nervous system disorders, oncology, and virology (including HIV, HBV, and respiratory infections). The firm leads, co-leads, or takes membership roles in investing syndicates and supports biopharma and diagnostics accelerators, with a portfolio of 15+ companies spanning drug discovery, preclinical CRO services, and clinical-stage assets across the US, Netherlands, Portugal, Finland, and Australia. Core portfolio companies include Viriom (HIV/HBV therapeutics), Avelas Biosciences (cancer surgery imaging), Chromis Therapeutics (HBV cure), Leap Therapeutics (DKK1 oncology antibody), Context Therapeutics (women's oncology), Vaxxas (needle-free vaccine delivery), Afraxis (CNS preclinical CRO), Polku Therapeutics (neurodegenerative), BIMINI Biotech (hematological cancers), Mair Therapeutics (Parkinson's), Mondego Bio (PTPN2 immuno-oncology), and Celyn Therapeutics (AI-designed pan-EGFR inhibitor). The investment team of 6–8 professionals is led by Managing Member Nikolay Savchuk (Ph.D., 100+ patents) and Founding President Ronald Demuth, with senior scientific oversight from Head of Due Diligence Michael Palfreyman (Ph.D., DSc; 35 US patents, 150+ publications).

The firm's core technology infrastructure is anchored by the i2020 Accelerator, a two-year program that de-risks early-stage drug discovery platforms toward advanced lead and clinical candidate stage, supported by AI and computer-aided drug design partnerships with Molsoft LLC and ChemDiv Inc. The portfolio also includes the integrated CRO Afraxis (patented ESP/Enhanced Spine Profiling technology) and the Loch platform — a $68.5M+ co-investment vehicle with OrbiMed across 9 companies targeting cancer, immunological, and neurodegenerative diseases. Revenue is generated through traditional venture fund mechanics — management fees and carried interest on investment returns — realized via capital appreciation of portfolio companies, pharma partnering transactions, and M&A exits. Customer segments are early-stage biotech companies seeking funding and operational support, institutional co-investors (notably OrbiMed, with $19B+ AUM), and pharmaceutical partners seeking acquisition or licensing targets in CNS, oncology, and virology.

Name

Torrey Pines Investment

Legal name

Torrey Pines Investment LLC

Website

http://torreypinesinv.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Torrey Pines Investment is a privately held San Diego-based specialty life-science venture capital firm founded in 2012 that leads and co-leads syndicates in early-stage biotech assets across CNS, oncology, and virology, deploying capital through its i2020 Accelerator and Loch platform alongside partners including OrbiMed.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Life science venture capital
• Biotech early stage investment
• Pharmaceutical seed funding
• Drug discovery accelerator
• Biotech portfolio management

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns: Torrey Pines Investment generates returns through capital appreciation of portfolio companies, realized gains from pharma partnering and M&A transactions, and co-investment returns from syndicate investments in early-stage biotech assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Torrey Pines Investment LLC is a specialty life-science venture capital firm that invests in early-development-stage biotech assets in CNS, oncology, and virology areas, typically targeting clinical proof-of-concept within a three-year horizon. The firm leads, co-leads, or takes membership roles in investing syndicates (notably with OrbiMed) and provides portfolio companies with hands-on operational support across drug discovery, non-clinical/clinical studies, manufacturing, quality, and regulatory affairs, including through the i2020 Accelerator program that accelerates early-stage drug discovery platforms to clinical candidate level within a two-year framework.

Product overview

Torrey Pines Investment is a specialty life-science venture capital and investment firm founded in 2012 in San Diego, CA, that supports biopharma and diagnostics companies through investment and operational expertise. The firm invests in early development stage assets from pharma and biotech partners in CNS, oncology, and virology areas, bringing them to success through pharma partnering and M&A. The portfolio includes nine portfolio companies spanning drug development across multiple therapeutic areas: Viriom (HIV/HBV treatments), Avelas Biosciences (cancer surgery imaging), Chromis Therapeutics (Hepatitis B), i2020 Accelerator (drug discovery), Leap Therapeutics (DKK1 antibody oncology), Afraxis (CNS preclinical CRO), Vaxxas (needle-free vaccine delivery), Context Therapeutics (women's oncology), and Polku Therapeutics (neurodegenerative diseases).

Differentiator

Problem solved

Functional benefit

Products and services

• i2020 Accelerator Program A two-year drug discovery acceleration program that supports early-stage biotech companies in advancing their discovery platforms towards advanced lead and clinical candidate level. The accelerator provides AI and computer-aided drug design capabilities through partnerships with Molsoft LLC and ChemDiv Inc., targeting programs in immunology, infectious diseases, oncology, and other therapeutic areas.

Quantifiable outcome

• Supported biopharma and diagnostics accelerators with assets achieving clinical POC within 3-year timeframe
• +1 more outcomes

Named customers14 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• ChemDiv Inc.coreTechnology or IntegrationChemDiv provides AI and computer-aided drug design services supporting the Loch platform and i2020 Accelerator programs. The partnership has been extended for discovery and early development on PTPN2 immuno-oncology programs for Mondego Bio.
• Molsoft LLCcoreTechnology or IntegrationMolsoft LLC provides AI and computer aided drug design capabilities supporting the Loch platform and i2020 Accelerator programs for novel small molecule development targeting cancer, immunological and neurodegenerative diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• OrbiMed: Global healthcare-dedicated investment firm with over $19B AUM that co-leads the i2020 Accelerator and Loch platform with Torrey Pines across multiple early-stage biotech deals. Closest operational peer given shared deal flow, co-investment frequency, and therapeutic focus.
• ARCH Venture Partners: Premier early-stage life-sciences VC that builds and incubates biotech companies from university and corporate spinouts. Directly comparable to Torrey Pines given early-stage bias, founder-company creation model (similar to i2020 Accelerator), and CNS/oncology orientation.
• Atlas Venture: Early-stage life-sciences VC that builds biotech companies from inception through clinical proof-of-concept, with strong transatlantic presence. Comparable to Torrey Pines in fund size, stage focus, and company-creation approach, including European deal flow similar to BIMINI/Mair/Mondego investments.
• 5AM Ventures: Early-stage life-sciences VC focused on formation-stage and Series A biotech with therapeutic breadth across CNS, oncology, and rare disease. Direct peer to Torrey Pines given similar check size, stage focus, and scientific founder orientation.
• Versant Ventures: Healthcare-dedicated VC with strong emphasis on company creation in early-stage biotech, including Inception Therapeutics-style incubators. Comparable to Torrey Pines given stage focus, therapeutic breadth, and use of in-house operating capabilities to underwrite and build companies.
• SV Health Investors: Healthcare-focused VC investing across biotech, medtech, and digital health, with particular strength in CNS and rare disease (Dementia Discovery Fund). Closely aligned with Torrey Pines' CNS emphasis and similar check size at formation and Series A stages.
• venBio: Biotechnology-focused VC that leads formation and Series A rounds in therapeutic areas including oncology and infectious disease. Comparable to Torrey Pines given stage focus, therapeutic areas, and tendency to partner with larger investors on follow-on rounds.
• Abingworth: Transatlantic life-sciences VC investing from company creation through late-stage with notable presence in UK and EU biotech formation. Comparable to Torrey Pines given European deal flow (Abingworth's UK/EU presence mirrors Torrey Pines' Netherlands/Portugal activity) and clinical-stage orientation.
• Pappas Capital: Specialty life-sciences VC investing in early-to-mid-stage biotech and medtech with strong CNS and therapeutic-area focus. Comparable to Torrey Pines given firm size, sector specialization, and concentration in CNS/oncology assets.

Broad incumbents

• Alexandria Venture Investments: CVC arm of Alexandria Real Estate Equities providing strategic venture funding to life-sciences companies across stages and therapeutic areas. Broader incumbent peer that overlaps with Torrey Pines' life-sciences investing universe but with significantly larger AUM and real-estate-driven strategic mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TorreyPinesInv

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments33 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torrey Pines Investment